← Eichor
Study identifier: NCT06895486 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation

Condition: Poliomyelitis  ·  Sponsor: PATH

PhasePhase 2
Planned participants675
Who can joinAll sexes, 6 Weeks to 7 Weeks
Healthy volunteersYes

About this study

The purpose of this study is to evaluate the safety and tolerability of co-administration of nOPV1 + nOPV2 in infants, relative to those receiving monovalent nOPV vaccines alone and whether two and/or three doses of co-administered nOPV1 and nOPV2 are non-inferior to corresponding doses of nOPV1 alone and nOPV2 alone.

This description comes directly from the study's public registry record.

Talk to the study team

Xavier Saez-Llorens  ·  +507-398-4386  ·  xavier.saez-llorens@cevaxin.com

Always discuss trial participation with your own doctor first.

Locations (3)

Cevaxin - 24 de DiciembrePanama City, PanamaRecruiting
Cevaxin - Ave. MéxicoPanama City, PanamaRecruiting
Cevaxin - ChorreraPanama City, PanamaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06895486